Immunomedics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 10/23/2020)
Today's Range
50-Day Range
52-Week Range
Average Volume4.01 million shs
Market Capitalization$20.31 billion
P/E RatioN/A
Dividend YieldN/A

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter.

Immunomedics logo

About Immunomedics

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.50 out of 5 stars

Medical Sector

1033rd out of 1,351 stocks

Diagnostic Substances Industry

15th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

Is Immunomedics a buy right now?

0 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last twelve months. There are currently for the stock. The consensus among Wall Street equities research analysts is that investors should "n/a" Immunomedics stock.
View analyst ratings for Immunomedics
or view top-rated stocks.

What stocks does MarketBeat like better than Immunomedics?

Wall Street analysts have given Immunomedics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Immunomedics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.39. The biopharmaceutical company had revenue of $20.07 million for the quarter, compared to analyst estimates of $24.81 million.
View Immunomedics' earnings history

What price target have analysts set for IMMU?

0 Wall Street analysts have issued 1-year target prices for Immunomedics' stock. Their forecasts range from $10,000,000.00 to $0.00. On average, they expect Immunomedics' stock price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%.
View analysts' price targets for Immunomedics
or view top-rated stocks among Wall Street analysts.

Who are Immunomedics' key executives?

Immunomedics' management team includes the following people:
  • Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 49, Pay $147.53k)
  • Mr. Usama Malik, CFO & Chief Bus. Officer (Age 45, Pay $533.39k)
  • Mr. Brendan P. Delaney, Chief Commercial Officer (Age 45, Pay $527.63k)
  • Mr. Bryan Ball, Chief Quality Officer (Age 50, Pay $646.48k)
  • Mr. William Fricker, Principal Accounting Officer, Exec. Director & Corp. Controller (Age 55)
  • Ms. Phyllis Parker, Director of Admin.
  • Dr. Chau Cheng, Sr. Director of Investor Relations
  • Mr. Jared Freedberg, Gen. Counsel & Corp. Sec. (Age 52)
  • Mr. Kurt J. W. Andrews, Chief HR Officer (Age 51)
  • Dr. Loretta M. Itri, Chief Medical Officer (Age 70)

Who are some of Immunomedics' key competitors?

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include (CELG), Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC).

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $87.86.

How much money does Immunomedics make?

Immunomedics has a market capitalization of $20.31 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Immunomedics have?

Immunomedics employs 366 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is

Where are Immunomedics' headquarters?

Immunomedics is headquartered at 300 AMERICAN RD, MORRIS PLAINS NJ, 07950.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.